Table 1 General description of patients, previous history and chronic therapy
Variable | All (n = 117) | ICU survivors (n = 58) | ICU non-survivors (n = 59) | Statistics (p) |
|---|---|---|---|---|
Age, years | 77 ± 5 | 76 ± 5 | 77 ± 5 | 0.2 |
Gender, female/male, n | 31 / 86 | 22 / 36 | 9 / 50 | 0.2 |
Height, cm | 173 ± 7 | 173 ± 7 | 173 ± 8 | 0.6 |
Body weight, kg | 87 ± 16 | 91 ± 18 | 84 ± 14 | 0.023a |
COVID-19 symptomsb, days | 7 ± 4 | 7 ± 4 | 7 ± 4 | 0.9 |
ICU LOS, days | 10.7 ± 9.0 | 8.8 ± 8.3 | 12.6 ± 9.3 | 0.02a |
Hospital LOS, days | 19.5 ± 10.8 | 21.3 ± 10.5 | 17.9 ± 10.9 | 0.09 |
Previous history: | ||||
LV hypertrophy, n (%) | 21 (18) | 13 (22) | 8 (14) | 0.3 |
Malignant disease, n (%) | 23 (20) | 13 (22) | 10 (17) | 0.6 |
Arterial hypertension, n (%) | 81 (70) | 40 (70) | 41 (70) | 0.9 |
Diabetes, n (%) | 42 (36) | 21 (36) | 21 (36) | 0.9 |
COPD, n (%) | 13 (11) | 6 (11) | 7 (12) | 0.5 |
Chronic kidney failure, n (%) | 22 (19) | 10 (17) | 12 (20) | 0.8 |
Therapy at home: | ||||
Statins, n (%) | 37 (32) | 20 (35) | 17 (29) | 0.3 |
Beta-blocker, n (%) | 47 (40) | 24 (42) | 23 (39) | 0.4 |
Inhalation corticosteroids, n (%) | 16 (14) | 8 (14) | 8 (14) | 0.6 |
ACE inhibitors, n (%) | 48 (41) | 23 (40) | 25 (42) | 0.5 |
Insulin, n (%) | 13 (11) | 6 (11) | 7 (12) | 0.5 |
Aspirin, n (%) | 34 (29) | 18 (32) | 16 (32) | 0.4 |
Diuretics, n (%) | 25 (22) | 13 (23) | 12 (20) | 0.5 |